Analyzing the Impact of ACIP’s Vote to Separate MMRV Vaccine

weyo - stock.adobe.com

The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to fundamentally shift US vaccine policy by recommending that children receiving their first immunization dose against measles, mumps, rubella, and varicella (chickenpox) (MMRV) receive separate injections instead of the single, combined four-part vaccine. The decision was made via an 8-3 vote with one abstention, according to published reports (1,2).

The decision advises separating the MMR vaccine from the varicella vaccine for children four years old and younger, which, in other words, recommends against the use of the combined MMRV vaccine (marketed as Merck & Co.’s ProQuad, which was approved by FDA in 2005 [3]). ACIP recommendations typically determine which vaccines are provided free through the US government and influence state laws, as well as shape health insurance coverage.

What is the technical rationale behind ACIP’s decision?

The catalyst for this significant regulatory change appears rooted in epidemiological data concerning the incidence of febrile seizures. Panelists advocating for the split pointed to evidence indicating that the combined MMRV shot carries approximately double the rate of fever-related convulsions in the four-year-old-and-younger age group compared with the separate administration of the MMR and varicella shots (4).

Data indicate the combined shot yields roughly seven to eight febrile seizures per 10,000 children, versus roughly three to four per 10,000 for those receiving MMR and varicella separately. Receiving the MMRV vaccine can trigger an estimated one additional febrile seizure per every 2300 to 2600 children, compared with the MMR vaccine alone (5,6). While febrile seizures occur in 2% to 5% of young children, are generally common, and carry an excellent prognosis (7), some new panel members argued that reducing their incidence is a beneficial public health goal, citing research that suggests potential detrimental effects on neurodevelopment.

In counterpoint, committee member Cody Meissner, MD, professor of Pediatrics at Geisel School of Medicine, Dartmouth stated in one of the published reports, "It’s a very frightening experience, but I think people are very comfortable in saying that a febrile seizure is not associated with any sort of impaired performance or neurocognitive development or school problems" (1).

What concerns exist over patient adherence and disease risk?

A key professional concern for vaccine manufacturers related to separating the vaccine regimen centers around the established benefit of combination vaccines in enhancing patient adherence to the childhood immunization schedule. Experts have warned that increasing the number of vaccinations required could threaten children’s health because it may likely increase the risk of non-compliance (8).

Preventable diseases, such as measles, mumps, rubella, and chickenpox, can be highly dangerous as evidenced by the fact that, prior to the measles vaccine in the 1960s, there were 48,000 annual hospitalizations (9). Opponents of the change emphasized that compliance risks outweigh the benefit of reducing the small incidence of febrile seizures.

"The disadvantage of giving two doses or, as was suggested, separating the two doses is that we know compliance falls. And the advantage of combination vaccines is that children and adults are more likely to complete the vaccine," Meissner said in the published report (1).

What impact will regulatory ambiguity and panel dynamics have on the industry?

Despite the new policy recommendation to split doses, the ACIP subsequently voted 8-1 not to change coverage for the combined MMRV shot within the Vaccines for Children (VFC) program. This subsequent vote to retain VFC coverage for the combined shot led to confusion among committee members regarding whether guidelines would differ based on the child's coverage. This contentious regulatory environment is furthermore heightened by the fact that Health and Human Services Secretary Robert F. Kennedy Jr., who has questioned vaccine safety, recently fired the previous ACIP members and replaced them with handpicked advisers, some of whom lack documented vaccine expertise (10).

CDC officials estimate that the practical shift of the new policy may be limited because only about 15% of children in the relevant age group currently receive the four-part shot, according to the CDC, which noted that this figure is already influenced by its previous evaluation and communication of the seizure risk in 2008 and 2009. The ACIP is scheduled to continue its meetings, which will include discussions on COVID-19 vaccines and votes on hepatitis B vaccination timing.

References

1. Sherman, C. CDC Panel Recommends Multiple Shots for Measles, Mumps, Rubella and Chickenpox Instead of Single Vaccine. theguardian.com, Sept. 18, 2025 (accessed Sept. 19, 2025).
2. Gardner, J. CDC Panel Recommends Splitting Measles, Varicella Shots. biopharmadive.com, Sept. 18, 2025 (accessed Sept. 19, 2025).
3. FDA. ProQuad Label (accessed Sept. 19, 2025). https://www.fda.gov/media/119880/download
4. MacDonald, S. E.; Dover, D. C.; Simmonds, K. A.; Svenson, L. W. Risk of Febrile Seizures After First Dose of Measles-Mumps-Rubella-Varicella Vaccine: A Population-Based Cohort Study. CMAJ 2014, 186 (11), 824–829. DOI: 10.1503/cmaj.140078
5. Klein, N. P.; Fireman, B.; Yih, W. K.; et al. Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures. Pediatrics 2010, 126 (1), e1-8. DOI: 10.1542/peds.2010-0665
6. World Health Organization. Information Sheet: Observed Rate of Vaccine Reactions Measles, Mumps and Rubella Vaccines. Who.int, May 2014.
7. Tiwari, A.; Meshram, R. J.; Kumar Singh, R. Febrile Seizures in Children: A Review. Cureus 2022, 14 (11), e31509. DOI: 10.7759/cureus.31509
8. Ventola, C. L. Immunization in the United States: Recommendations, Barriers, and Measures to Improve Compliance. Part 1: Childhood Vaccinations. P T. 2016, 41 (7), 426–436.
9. Wharton, M. E. Measles Elimination in the United States. J. Infect. Dis. 2004, 189 (Supplement_1), S1–S3. DOI: 10.1086/377693
10. Cole, C. Biopharma Impacts of Paul Offit's Ousting from FDA Vaccine Panel. BioPharmInternational.com, Sept. 3, 2025.